BiotechTube
Home/Xeris Pharmaceuticals/Kenneth E. Johnson, Pharm.D.
KE

Kenneth E. Johnson, Pharm.D.

Chief Commercial Officer

Xeris Pharmaceuticals

Therapeutic Areas

EndocrinologyNeurologyMetabolic

Xeris Pharmaceuticals Pipeline

DrugIndicationPhase
Gvoke® (glucagon)Severe HypoglycemiaMarketed
Keveyis® (dichlorphenamide)Primary Periodic ParalysisMarketed
Recorlev® (levoketoconazole)Endogenous Cushing’s SyndromeMarketed
XP-8121Undisclosed Metabolic IndicationPhase 2
XP-19986Undisclosed CNS IndicationPhase 1
XP-6341Undisclosed Endocrine IndicationPhase 1

Leadership Team at Xeris Pharmaceuticals

PR
Paul R. Edick
Chairman and Chief Executive Officer
BM
Barry M. Deutsch
Chief Financial Officer
SP
Steven Prestrelski, Ph.D.
Chief Scientific Officer, Co-founder
JP
John P. Schmid
Chief Business Officer
View full Xeris Pharmaceuticals profile